HEDIS® Results
Medicaid HEDIS® Annual Rates.
Molina’s scores for the past two years are below. You can see how Molina performs compared to our target goal.
Measure / Data Element |
2020 |
2021 |
2021 Goal |
Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA) |
69.52% |
71.79% |
67.60% |
Annual Dental Visits (ADV) |
NB |
NB |
50.00% |
Antidepressant Medication Management (AMM) Effective Continuation Phase Treatment |
41.87% |
42.12% |
42.90% |
Appropriate Testing for Pharyngitis (CWP) |
46.59% |
44.96% |
80.70% |
Appropriate Treatment for Upper Respiratory Infection (URI) |
90.21% |
90.58% |
90.80% |
Asthma Medication Ratio (AMR) Total |
56.22% |
60.39% |
68.40% |
Avoidance of Antibiotic Treatment for Acute Bronchitis / Bronchiolitis (AAB) |
48.51% |
50.02% |
59.50% |
Breast Cancer Screening (BCS) |
60.45% |
55.83% |
56.70% |
Cervical Cancer Screening (CCS) |
58.88% |
57.18% |
62.00% |
Childhood Immunization Status (CIS) Combination #10 |
38.44% |
40.15% |
42.30% |
Chlamydia Screening in Women (CHL) Total |
65.11% |
61.24% |
60.10% |
Comprehensive Diabetes Care (CDC) BP Control < 140/90 |
67.40% |
54.26% |
63.20% |
Comprehensive Diabetes Care (CDC) HbA1c Control <8.0% |
51.09% |
50.12% |
49.60% |
Comprehensive Diabetes Care (CDC) Eye Exam |
60.83% |
59.85% |
55.80% |
Controlling High Blood Pressure (CBP) |
61.31% |
54.99% |
60.00% |
Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD) |
80.95% |
76.33% |
78.90% |
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (FUA) 7-Day Follow-Up Total |
NB |
3.84% |
16.30% |
Follow-Up After Emergency Department Visit for Mental Illness (FUM) 7-Day Follow-Up Total |
NB |
11.10% |
45.40% |
Follow-Up After Hospitalization for Mental Illness (FUH) 7-Day Follow-Up Total |
NB |
NB |
44.80% |
Follow-Up for Children Prescribed ADHD Medication (ADD) Continuation and Maintenance Phase |
39.81% |
39.05% |
60.30% |
Immunizations for Adolescents (IMA) Combination #2 |
36.98% |
39.42% |
41.80% |
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET) Engagement of AOD Treatment Total |
4.01% |
NB |
16.50% |
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) Total |
NA |
NA |
34.80% |
Pharmacotherapy Management of COPD Exacerbation (PCE) Systemic Corticosteroids |
68.35% |
65.38% |
73.60% |
Pharmacotherapy Management of COPD Exacerbation (PCE) Bronchodilator |
83.06% |
82.82% |
86.90% |
Prenatal and Postpartum Care (PPC) Timeliness of Prenatal Care |
95.62% |
89.29% |
88.30% |
Prenatal and Postpartum Care (PPC) Postpartum Care |
75.91% |
78.10% |
78.30% |
Risk of Continued Opioid Use (COU) 31-Day Total |
3.44% |
3.54% |
≤ 2.80% |
Statin Therapy for Patients with Cardiovascular Disease (SPC) Received Statin Therapy Total |
80.78% |
80.20% |
81.90% |
Statin Therapy for Patients with Cardiovascular Disease (SPC) Statin Adherence 80% Total |
71.87% |
75.95% |
74.90% |
Statin Therapy for Patients with Diabetes (SPD) Received Statin Therapy |
68.76% |
71.02% |
68.50% |
Statin Therapy for Patients with Diabetes (SPD) Statin Adherence 80% |
65.35% |
69.67% |
71.90% |
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP) Total |
NA |
NA |
66.40% |
Use of Imaging Studies for Low Back Pain (LBP) |
72.77% |
74.70% |
77.80% |
Use of Opioids at High Dosage (HDO) |
3.92% |
3.17% |
≤ 2.90% |
Use of Opioids from Multiple Providers (UOP) Multiple Prescribers and Multiple Pharmacies |
2.61% |
1.81% |
≤ 1.30% |
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) BMI Percentile |
86.37% |
86.86% |
80.60% |
NA = Not Available Due to Small Denominator
NB = No Benefit
NR = Not Reported
NQ = Not Required
BR = Biased Rate